The gaps between patient and physician understanding of the emotional and physical impact of osteoporosis by Rizzoli, René et al.
ORIGINAL ARTICLE
The gaps between patient and physician understanding
of the emotional and physical impact of osteoporosis
René Rizzoli & Maria Luisa Brandi &
Karsten Dreinhöfer & Thierry Thomas &
Denys A. Wahl & Cyrus Cooper
Received: 22 September 2010 /Accepted: 24 November 2010 /Published online: 9 December 2010
# International Osteoporosis Foundation and National Osteoporosis Foundation 2010
Abstract
Summary A multinational survey was conducted to evaluate
the gaps between patients and physicians understanding of
osteoporosis. The International Osteoporosis Foundation
recommends the creation of community-wide patient support
programmes to increase prevention and treatment awareness
of osteoporosis.
Introduction Osteoporosis is often undiagnosed and un-
treated, leaving millions of people at risk of debilitating
fractures. A survey was designed to investigate any gaps
that may exist between physician and patient knowledge of
osteoporosis, understand barriers to patient adherence and
identify ways to address unmet needs and improve
communications.
Methods Telephone interviews were conducted with
patients (n=844) and physicians (n=837) in 13 countries
in June/July 2009. Patients were women with postmeno-
pausal osteoporosis currently taking (or in the past 2 years)
prescribed medication. Physicians had experience in treat-
ing osteoporotic patients, which included only general
practitioners who saw ≥10 (exception: in Hungary ≥5)
and specialists who saw ≥20 patients with osteoporosis per
month.
Results Physicians consistently underestimated their
patients’ adherence to treatment and beliefs on the impact
of osteoporosis on their quality-of-life. Physicians under-
estimated how many patients worry about breaking a bone
(51% vs 79%), as well as patient concerns about declines in
activity levels (40% vs 70%), becoming dependent on
others (30% vs 60%) and not being able to work for longer
(30% vs 57%). Patients believed the most credible
osteoporosis information was from specialists (94%).
Patients (75%) would like easy to understand materials
and 49% would welcome inter-patient discussions of their
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condition. Most physicians (88%) believed that osteoporo-
sis organisations are among the most credible sources for
information, 80% would give patients written materials to
increase adherence and 76% would recommend patient
programmes that encourage better communication on
managing osteoporosis.
Conclusion Community-wide patient support programmes
may help patients to manage their concerns and address
unmet needs in osteoporosis management.
Keywords Osteoporosis . Survey . Patients and physicians .
Support programmes . Disease management
Introduction
Osteoporosis is characterised by reduced bone mass and it
predisposes a person to an increased risk of fracture [1].
Affecting more than 200 million people worldwide [2], it has
become a major health care issue. It results not only in loss
of bone mass, but significant problems with respect to
functional status and quality of life, including physical,
functional and psychosocial impairment, morbidity and
mortality [3]. For example, one of the most common
outcomes of postmenopausal osteoporosis is vertebral
fracture, which can lead to increased pain in normal day-
to-day activities thus limiting mobility and social activities,
and a reduction in self-confidence due to a loss of stature [4].
The general management of osteoporosis includes the
prevention of falls, maintenance of mobility, correction of
nutritional deficiencies (calcium, vitamin D and protein) [5]
along with prescription medication. The most common
current pharmacological options include bisphosphonates,
calcitonins, parathyroid hormone, selective oestrogen re-
ceptor modulators, strontium ranelate and denosumab [6].
Despite the availability of osteoporosis treatments for more
than 10 years, large numbers of osteoporotic fractures still
occur and the number is expected to increase [7]. The sites
of fractures are varied and of an estimated 9 million new
osteoporotic fractures worldwide in 2000, 1.7 million were
at the forearm, 1.6 million were at the hip, and 1.4 million
were clinical fractures of the vertebrae [8].
Adherence to osteoporosis therapy is often inadequate.
Studies show that fewer than 50% of patients are still taking
their prescribed medication after 1 year [9]. Inadequate long-
term adherence may result in wasted resources, an increased
fracture rate and no significant impact on the burden of
illness. A recent systematic review of poor adherence to and
persistence with osteoporosis medications found that few
interventions were efficacious and there was no reported
clear trends regarding successful intervention techniques
[10]. Potential reasons for non-adherence include miscon-
ceptions of personal risk, uncertainty of therapy benefits and
risks, side effects that are too great to tolerate or a belief in
the efficacy of lifestyle measures alone [11].
Since osteoporosis outcomes appear to be closely linked
to patient beliefs and concerns about the disease and its
management, it is essential to gain a better understanding of
these issues. The present study aimed to conduct a
multinational survey of patients with osteoporosis to (1)
investigate gaps that may exist between patient and
physician understanding of the emotional and physical
impact of osteoporosis, (2) identify barriers to patient
adherence to medication, and (3) understand the ways in
which osteoporotic patients can better share and receive
information about the management and treatment of
osteoporosis. To our knowledge, no survey of this scale
has been conducted to examine the beliefs of communica-
tion of patients towards physicians and vice versa.
Methods
Design
This was a telephone survey to investigate gaps that may exist
between physician and patient understanding of osteoporosis,
understand barriers to patient adherence, identify unmet needs
and improve communications. Structured telephone inter-
views lasting an average of 15–20 min were conducted over
5 weeks in June and July of 2009 with individuals who agreed
to participate. The questionnaire used in the survey was
validated by two pilot sessions in Germany and the UK.
Within each pilot session, three interviews were conducted to
ensure use of the most appropriate wording and optimal
logical flow for the survey.
Patient survey
Participants were considered eligible for inclusion in the
study if they were female and aged over 55 years, had
already gone through the menopause, were diagnosed with
postmenopausal osteoporosis by a physician, had visited a
physician for osteoporosis and were currently (or in the past
2 years) prescribed medication for osteoporosis.
To achieve a sample size of 80 patients in France,
Germany, Italy, Spain, UK and Australia, an average of
1,135 were contacted in each country. To achieve a sample
size of 50 patients in Austria, Belgium, Hungary, Greece,
Netherlands, Sweden and Switzerland, an average of 1,798
were contacted in each country.
Physician survey
Participants were considered eligible for inclusion in the
study if they had 3 to 35 years of experience in treating
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patients with osteoporosis, worked mainly in an office-
based setting and treated a minimum number of patients
suffering from postmenopausal osteoporosis in an average
month (at least ten patients for general practitioners/primary
care physicians [GPs/PCPs] and at least 20 patients for
specialists).
GPs/PCPs and specialists were in a 1:1 ratio for the total
number of participants per country; specialists were a
country-specific mix of rheumatologists, endocrinologists,
gynaecologists and orthopaedists. To achieve a sample size
of 80 physicians in Germany, France, Italy, Spain, UK and
Australia, an average of 411 per country were contacted. To
achieve a sample size of 50 physicians in Austria, Belgium,
Hungary, Greece, Netherlands, Sweden and Switzerland, an
average of 445 per country were contacted.
Interviews
Interviews were conducted by native speakers of the
relevant local language having at least 2 years experience
in the medical area. All interviewers were trained by the
local fieldwork manager through a personal briefing.
Before starting the survey in each country, three to four
test interviews were conducted internally to ensure the
interviewers’ familiarity with the wording and flow of the
questionnaire. The questions appeared sequentially so that
the interview could not continue until a response was
entered for each question; for some questions, an answer of
“do not know/no answer” was allowed. Participants in a
number of different regions in each country were contacted
to ensure that the data were representative.
The interview contained structured questions for patients
about the following: socio-demographic information, pre-
scription medication use in the past 2 years, disease history
(including diagnosis, symptoms), disease knowledge and
physician interaction. The interview contained structured
questions for the physicians about the following: their
specialty, number of patients with osteoporosis treated,
products prescribed and patient education provided.
Data analysis
Data are presented as the percentage of respondents
replying to each answer positively. t tests were conducted
for comparing patient responses with physician responses
at 5% risk level (normal averages). However, t tests were
only performed for those questions that were similar in
the patient and the physician questionnaires. Statistical
analyses were performed to assess gaps in the answering
behaviour of patients and physicians. Quantum or SPSS
were used to perform t tests on the proportions and means
at 5% risk level (differences were considered to be
significant at p<0.05).
Results
Sample
Patients
Out of a mean of 1,135 patients contacted in Germany,
France, Italy, Spain, UK and Australia, an average of 24%
of patients responded. From these, at least 80 eligible
patients from each of these countries took part in the
survey. The patient response rate for the Netherlands,
Austria, Belgium, Hungary, Greece, Sweden and Switzerland
was approximately 19%. In these countries, at least 50 eligible
patients took part in the survey. The total sample was 844
patients of varied economic and social status (see Table 1)
Table 1 Participants characteristics
Patients on HRT (%)
Yes 16.0
No 84.0
Education (%)
Left school with no qualifications 10.4
Primary school 21.1
Secondary school (GCSE/O levels) 38.5
6th form (A levels) 17.3
College/university 10.8
Post graduate 1.2
N/A 0.7
Employed (%)
Employed 16.4
Unemployed 9.1
Retired 67.9
N/A 6.6
Size of household (%)
1 person 28.1
2 people 54.7
3 people 10.8
4 people 3.6
5 people+ 2.6
N/A 0.2
Monthly household incomes € (%)
Up to 999 17.9
1,000–1,499 21.2
1,500–1,999 18.2
2,000–2,499 16.5
2,500–2,999 8.6
3,000–3,499 4.0
3,500–3,999 2.1
4,000+ 2.4
N/A 9.0
HRT hormone replacement therapy
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across the 13 countries, with a minimum of five regions
represented per country.
Physicians
Out of a mean of 411 physicians contacted in Germany,
France, Italy, Spain, UK and Australia, an average of 49%
of physicians responded. From these, at least 80 eligible
physicians from each country took part in the survey. The
physician response rate for the Netherlands, Austria,
Belgium, Hungary, Greece, Sweden and Switzerland was
approximately 32%. In these countries, at least 50 eligible
physicians from each country took part in the survey. The
total sample was 837 physicians (70% men, 30% women)
across the 13 countries, with a minimum of five regions
represented per country.
Patient and physician knowledge
A total of 69% of patients believed that they were well
informed about their disease, with 21% and 48% of patients
feeling very knowledgeable and knowledgeable, respec-
tively. Patients understood some of the main aspects of
osteoporosis; 93% described osteoporosis as a condition
that “causes bones to be brittle and fracture/break easily”,
73% knew that it is a “condition related to the menopause”
and 93% that it is “associated with reductions in bone
density” (Fig. 1). Patients also described osteoporosis as
“just a part of getting old” (57%), “caused by a lack of
calcium” (83%) and “a condition that could cause height
loss” (81%). Three quarters of patients also described
osteoporosis as “a condition that could result in a hunched
back over time”. Only 57% of physicians understood
osteoporosis in this way.
There was a large gap in the assessment of the major risk
factors between patients and physicians. Indeed, about one
in three patients could not identify any risk factors for
osteoporosis compared with 1% in the physician’s group.
Patient awareness was low for cortisone therapy (14%),
family history of hip fracture (27%) and nicotine use (20%)
compared with physician concerns over those risk factors
(67%, 79% and 50%, respectively).
Treatment adherence
The physicians’ estimate of the percentage of their
patients discontinuing their prescribed osteoporosis medi-
cation generally corresponded with their patients’ state-
ments. However, physicians substantially underestimated
the average duration of the discontinuation. Whereas
patients reported that they discontinued their osteoporosis
treatment for an average of 5.5 months, this was
2.6 months longer than the estimation of the physicians
(p<0.05). Physicians also estimated that 71% of their
patients forgot to take their treatment, while only 25% of
patients surveyed admitted to forgetting to take their
treatment. Up to 29% of patients did not see a problem
in missing a dose once in a while. Reasons patients did not
take medication are listed in Fig. 2 and included: wanting
to switch to an alternative (20%), the medication is not
helping (12%) and too many side effects (25%). Among
physicians, 87% indicated that they provided patients with
information on the importance of treatment adherence and
82% of the patients reported being informed by their
physicians on the importance of taking their treatment
continuously.
For patients, the desired features of an osteoporosis
treatment included one that works with other medication
Fig. 1 Understanding of osteo-
porosis, % of patients answering
“yes” to statements of how they
understand osteoporosis com-
pared with % of physicians
answering “yes” to statements
based on their explanations
given to patients about osteoporo-
sis; *p<0.05
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being taken (67%), has fewer side effects (58%), needs less
frequent dosing (58%), is easier to take (48%), affects daily
routine less (43%) and has less complicated dosing (37%).
There was a wide disagreement between patients and
physicians especially for less complicated dosing, easier to
take medication and fewer side effects. The differences
between the patients’ perspective compared with the physi-
cians perspective were −38%, −36% and −34%, respectively.
Quality of life
Large gaps between the two surveyed groups were reported
in attitudes towards the consequences of osteoporosis for
patients (Fig. 3). Physicians underestimated patients’ con-
cerns about the impact of osteoporosis on their daily life.
Among patients, 70% were afraid that they will not be as
active as they would like to be, while physicians estimated
this at only 40%. In addition, 60% of patients worried about
becoming more dependent on others as a result of their
osteoporosis, while physicians estimated this at only 31%.
There was no significant difference between patient–
physician responses to osteoporosis affecting social life
activities and feeling comfortable telling people they have
osteoporosis.
Of patients surveyed, 79% were worried about breaking
a bone due to their osteoporosis and 57% were afraid of not
being able to work for as long as they needed to. Among
physicians who were questioned about their patients’
beliefs, these were estimated at only 51% and 27%,
respectively.
Fig. 2 Experiences when taking
prescribed osteoporosis medica-
tions, % of patients answering
“yes” to statements compared
with % of physicians answering
“yes” to statements based
on their beliefs of their patients
agreeing to the statements;
*p<0.05
Fig. 3 Attitudes towards osteo-
porosis, % of patients answering
“yes” to statements compared
with % of physicians answering
“yes” to statements based
on their beliefs of their patients
agreeing to the statements;
*p<0.05
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Patient support tools
Patients believed that specialists (94%), GPs (88%) and
brochures from osteoporosis organisations (76%) are the
most credible sources of information on their osteoporosis.
Table 2 shows that 75% of patients wanted to receive
written information in terms they understood and 62% of
patients would find it helpful to have more frequent contact
with their physicians about their osteoporosis. Talking to
their friends about osteoporosis helped 60% of patients and
58% of patients requested a programme that builds their
emotional and physical confidence in managing their
osteoporosis. Almost half of all patients (49%) would
welcome opportunities to come together with other people
in their community to discuss day-to-day challenges of
living with osteoporosis.
Physician support
Table 3 shows that 88% of physicians believed that besides
a GP or specialist, brochures from osteoporosis organisa-
tions are one of the most credible sources for getting
information on osteoporosis. Of the physicians surveyed,
80% would hand out educational information to their
patients to enhance patient adherence to osteoporosis
therapy. Most (76%) were willing to recommend a patient
adherence programme to their patients, and 64% of
physicians believed that other osteoporotic patients are a
credible source of information for their patients. Physicians
assessed the credibility of most of osteoporosis information
sources significantly higher than patients did, including
patient support group/programmes, websites, nurse specialists
and books.
Table 2 Percentage of patients describing what type of support would be helpful in managing osteoporosis
Type of support Patients (%)
Written information in terms I understand 75
More frequent contact with health care professionals 62
Talking to my friends about osteoporosis personally 60
More readily available/acceptable information from trusted sources offered in my community (i.e., wellness centre, library) 59
A programme that builds my emotional and physical confidence in managing my osteoporosis 58
Better understanding of why I need to take my treatments 50
Opportunities to come together with other people in my community to discuss day-to-day challenges of living with osteoporosis 49
Table 3 Credibility of information sources, % of patients and physicians answering “yes” to statements that they believe are most credible for
getting osteoporosis information; *p<0.05
Information Source Patients (%) Physicians (%) Gap (from patients’ perspective)
Patient support group/programme 49 76 −27*
Websites 34 59 −25*
Nurse (UK: nurse specialist) 53 68 −15*
Books 52 65 −14*
Brochures from osteoporosis organisations 76 88 −12*
Radio programmes 38 47 −9*
Public places with information booths (shopping malls, etc.) 21 29 −7*
Other osteoporotic patients 58 64 −6*
General Practitioner 88 95 −6*
Specialist 94 99 −5*
Friends, family and colleagues 48 44 4
Pharmacy/health magazines 70 73 −3
Newspapers 37 40 −3
Pharmacist 73 76 −3
Women’s magazines 40 37 3
TV health programmes 57 56 1
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Discussion
The surveyed patients believed that they were better
informed about their osteoporosis than the data revealed.
More than two thirds felt very knowledgeable about their
disease and the majority described the disease as a
condition that “causes bones to be brittle and fracture/break
easily”. However, over half of the surveyed patients
incorrectly described osteoporosis as “just a part of getting
old”. Other studies have reported data about the lack of
patient knowledge in osteoporosis. Women (n=437) from
rural Washington and Oregon underestimated their risk of
osteoporosis, lacked basic knowledge about the prevention
of osteoporosis and did less exercise than that recommen-
ded [12]. A low perception of osteoporosis and the uptake
of screening services were reported in a study with Belgian
women working in a university hospital in Brussels. Three
times more of these women had undergone a mammogra-
phy than a bone mineral density test [13].
Of the patients surveyed here, one in three could not
identify any risk factors for osteoporosis. This highlights a
lack of disease understanding, which needs to be addressed.
In a study that looked at the knowledge and risk
perceptions about osteoporosis and its treatment in older
US women, it was reported that the health impact of
osteoporosis was undervalued [14]. Women considered the
disease to be controllable, not dreaded (considering other
possible diseases) or life threatening. There was also
confusion between arthritis and osteoporosis in a third of
older women in a diagnosed and general sample. Scores
were highest for the women on knowledge questions related
to items that they could control, such as diet and exercise,
and women who understood how their behaviour would
affect osteoporosis were likely to act on that knowledge
[14].
This survey found that patients fear fractures, yet their
adherence to treatment is poor. Patients reported that they
stopped taking their osteoporosis treatment for about
5.5 months on average, and approximately, a third of
patients did not see a problem in missing a dose once in a
while. Although they admitted to receiving information on
the importance of taking their osteoporosis medicine, they
did not fully understand that adherence significantly
reduces fracture risk. Other studies of non-adherence
include a national UK survey for women (n=533) over
the age of 50 with osteoporosis who were taking or had
taken bisphosphonate therapy within the previous 12months
[15]. Self-reported non-adherence to bisphosphonates (daily
and weekly) was found to be independent of non-persistence
(the decision to stop taking treatment). In this study, the
reasons patients reported that they did not take medication
included too many side effects (25%), wanting to switch to
an alternative (20%) or that the medication was not helping
(12%). The side effects and other factors associated with
non-persistence were thought to be modifiable in clinical
practice through information, education and concordant
partnerships [15].
The majority of physicians surveyed indicated that they
proactively provided patients with information on the
importance of treatment adherence and believed the average
duration patients discontinued treatment to be 2.9 months.
The gap of 2.6 months between the average duration of
patients stopping osteoporosis treatment and the physician
perceived time, and the wide disagreement in the desired
features of osteoporosis treatment between the groups need
to be addressed. Besides proactive information when
treatment is first given, a source of supporting or
supplemental information would help provide and reaffirm
knowledge. Other studies have reported that the patient–
health care provider relationship is a key factor that affects
adherence [16]. In this study, focus groups were conducted
in postmenopausal women (n=37) on at least one prescrip-
tion or over-the-counter medication for osteoporosis. From
these groups, it was reported that approximately 50% of
women who took pharmacotherapy for osteoporosis dis-
continued within a year [16].
From the results of this survey, the impact of osteoporosis
on patient quality of life is significantly underestimated by
physicians. The quality of life questions were grouped into
three general categories, activity and independence, emo-
tional fear of fracture and employment status. In all of these
categories, physicians believed patients to be less concerned
than the patients actually reported. The gaps between patient
and physician responses on quality of life were approxi-
mately 30% in this study, which represents a significant
discrepancy that needs to be resolved.
In order to improve patient knowledge and adherence
and address potential gaps in patient–physician perceptions,
patient support tools were investigated. It was found that
patients would like easy to understand tools and greater
interaction with their physicians and other patients to help
manage their osteoporosis. This need for patient support is
an ongoing issue as shown by the results from a study
conducted in the 1990s highlighting that both education and
screening motivated lifestyle changes and are central to
osteoporosis prevention [17]. White women (n=771) aged
30 years and over without a diagnosis of osteopenia or
osteoporosis responded to a questionnaire about an osteo-
porosis educational programme. Only 16% of participants
reported that their doctors had discussed osteoporosis with
them [17]. Patient support is still a current issue for
osteoporosis. In a 2006 clinical review on osteoporosis
and its management, it was stated that compliance and
persistence with treatments need to be improved and this
can be achieved by better patient education and evaluating
dosing regimens [18].
Arch Osteoporos (2010) 5:145–153 151
The most credible sources of information on osteoporo-
sis for patients surveyed here were specialists, GPs and
brochures from osteoporosis organisations. Patients want
this information more frequently and in terms they can
understand. This is in agreement with a study of women in
the USA, which concluded that health care providers were
the preferred source of information about osteoporosis [12].
However, a recent study [19] reported that passive patient
education with printed information alone does not appear to
be very effective. Indeed, the difference in adherence at
12 months between the treatment group and the control
group was not significant when an educational osteoporosis
leaflet alone was used. The use of patient reminder
programmes and nurse monitoring has also been reported
as beneficial [19], and another study investigating the
perceptions and beliefs surrounding future fracture risk in
osteoporotic patients concludes that messages about frac-
ture risk would be better emphasised by well-designed
written materials with attention grabbing graphics and as
part of a nationwide post-fracture care initiative [20].
Patients in our survey also reported that talking to their
friends about osteoporosis was beneficial and that they
would value interaction with other people in their commu-
nity to discuss day-to-day challenges of living with
osteoporosis.
Surveyed physicians support patient programmes and are
eager for tools that will help them better educate their
patients about osteoporosis. Eight out of ten physicians in
this survey would hand out educational information to their
patients with approximately nine out of ten believing that
brochures from osteoporosis organisations are one of the
most credible sources for osteoporosis information. Physi-
cians gave significantly more credibility to patient support
groups, programmes and websites as information sources
on osteoporosis than patients did. A dedicated website
could provide a useful resource for osteoporotic patients,
and a study looking at the idea of web-based care for
certain components of osteoporosis management and
education found that middle-aged women were receptive
to the concept [21].
Like any survey, those who chose to respond
(approximately 19% to 24% of patients and 32% to
49% of physicians) could hold systematically different
experiences and therefore beliefs than those who did not.
The low proportion of patients and physicians that chose
to participate brings a certain bias that attenuates the
conclusions of this survey and should be considered
when assessing the results. Also poor memory or
misunderstanding of the questions can contribute to
inaccuracies in the data. Despite these limitations, there
are clear disparities in patient and physician perceptions
of osteoporosis, which indicate a need for increased
patient support.
Conclusions
Results from this multinational survey show that patients
are not as well informed as they believe and worry about
their quality of life, but do not always adhere to treatment.
The link between fracture prevention and treatment adherence
is not fully understood by patients as they fear fractures but
discontinue or miss doses of their treatment. Physicians
underestimate their patients’ concerns about quality of life,
but are willing to endorse programmes encouraging better
communication/education on managing osteoporosis. Ini-
tiation of a community-wide programme may enable
patients to manage their concerns and address unmet needs
in the management of osteoporosis. The programme should
be:
& Easy to understand
& Improve patient–physician dialogue
& Allow patient–patient contact
& Encourage treatment adherence/persistence
& Help patients to maintain or improve their quality of life
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